Geneva Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Geneva Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$687K	Buy	6,642 +4,188	+171%	+$412K	0.01%	440
2017 Q1	$240K	Buy	2,454 +27	+1%	+$2.58K	﹤0.01%	644
2016 Q4	$215K	Sell	2,427 -765	-24%	-$69.6K	﹤0.01%	660
2016 Q3	$308K	Buy	+3,192	New	+$304K	0.01%	573
2015 Q3	–	Sell	-4,725	Closed	-$581K	–	666
2015 Q2	$581K	Buy	4,725 +1,635	+53%	+$196K	0.01%	404
2015 Q1	$354K	Buy	3,090 +705	+30%	+$77.8K	0.01%	482
2014 Q4	$241K	Buy	+2,385	New	+$232K	﹤0.01%	566

Other funds holding IBB

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Geneva Advisors's IBB Position: Q2 2017 in Review

Geneva Advisors increased its iShares Biotechnology ETF (IBB) stake by 171% in Q2 2017, buying an estimated $412K and bringing the position to 6,642 shares worth $687K. The position accounts for 0.01% of the portfolio, ranked #440.

Geneva Advisors first reported a position in IBB in Q4 2014 and has held it in 7 quarters since. 562 funds tracked by Wall St. Rank hold IBB as of Q2 2017.

Geneva Advisors held 6,642 shares of iShares Biotechnology ETF worth $687K as of Q2 2017.
Geneva Advisors bought 4,188 iShares Biotechnology ETF shares in Q2 2017, an estimated $412K.
iShares Biotechnology ETF made up 0.01% of Geneva Advisors's portfolio in Q2 2017, its #440 holding.
Geneva Advisors first reported a position in iShares Biotechnology ETF in Q4 2014 and has held it in 7 quarters since.
562 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.